Figure 2
Figure 2. Stirring enhances latent TGF-β1 activation. (A) Platelet releasate or (B) serum (200 μL) was placed in a glass aggregometer cuvette containing a metal stir bar and incubated at 37°C with and without stirring (1200 rpm) for the indicated time periods. Active TGF-β1 was measured directly in the ELISA, whereas total TGF-β1 (latent + active) was measured after activating latent TGF-β1 by treatment with acid. Stirring dramatically increased the amount of active TGF-β1 in both platelet releasates (3.5 ± 0.5 ng/mL, P < .001; n = 3) and sera (2.5 ± 0.6 ng/mL, P < .001; n = 4). Increasing the stirring speed enhanced latent TGF-β1 activation in both platelet releasates (C) and sera (D) when measured after 2 hours. Error bars represent SD. (E) MLECs were stimulated for 2 hours in serum-free medium with stirred or unstirred platelet releasates in the presence or absence of anti–TGF-β1 neutralizing antibody (α–TGF-β1; 2 μg/mL). Smad2 phosphorylation was detected by immunoblotting with a mAb specific for phosphorylated Smad2 (P-Smad2), and total Smad2 was detected with a polyclonal antibody that reacts with both phosphorylated and unphosphorylated Smad2. Exposure to platelet releasates stirred at 1200 rpm increased the amount of phosphorylated Smad2 but not total Smad2.

Stirring enhances latent TGF-β1 activation. (A) Platelet releasate or (B) serum (200 μL) was placed in a glass aggregometer cuvette containing a metal stir bar and incubated at 37°C with and without stirring (1200 rpm) for the indicated time periods. Active TGF-β1 was measured directly in the ELISA, whereas total TGF-β1 (latent + active) was measured after activating latent TGF-β1 by treatment with acid. Stirring dramatically increased the amount of active TGF-β1 in both platelet releasates (3.5 ± 0.5 ng/mL, P < .001; n = 3) and sera (2.5 ± 0.6 ng/mL, P < .001; n = 4). Increasing the stirring speed enhanced latent TGF-β1 activation in both platelet releasates (C) and sera (D) when measured after 2 hours. Error bars represent SD. (E) MLECs were stimulated for 2 hours in serum-free medium with stirred or unstirred platelet releasates in the presence or absence of anti–TGF-β1 neutralizing antibody (α–TGF-β1; 2 μg/mL). Smad2 phosphorylation was detected by immunoblotting with a mAb specific for phosphorylated Smad2 (P-Smad2), and total Smad2 was detected with a polyclonal antibody that reacts with both phosphorylated and unphosphorylated Smad2. Exposure to platelet releasates stirred at 1200 rpm increased the amount of phosphorylated Smad2 but not total Smad2.

Close Modal

or Create an Account

Close Modal
Close Modal